Reminder: Roche ’s virtual event on key ophthalmology data presented at the Angiogenesis 2022 Meeting

   We are pleased to invite investors and analysts to participate in our virtual event onMonday,14 February 2022, highlighting Roche data presented at the virtual Angiogenesis, Exudation, and Degeneration 2022 Meeting, from 11th to 12th February. 16:30 – 17:45 CET / 15:30 - 16:45 GMT10:30 – 11:45 am EST / 7:30 – 8:45 am PST  The webinar will start with a presentation, followed by a Q&A session (live access to the speakers). The slides will be available for download at 15:00 CET on the day of the event.>click here AgendaOphthalmology franchise strategyNilesh Mehta, Global Franchise Head, Ophthalmology Ophthalmology clinical developmentChristopherBrittain, Vice President and Global Head of Ophthalmology Product Development Angiogenesis highlights2-Year data for Susvimo in nAMD (Ph III Archway)2-Year data for Vabysmo in DME (Ph III YOSEMITE& RHINE)NancyHolekamp, M.D., Retina Specialist Access to virtual event (pre-registration required)Please pre-register for our webinarhere*.  Should you be unable to register for the webinar due to your company IT policy, please send an e-mail [e-mail].  A replay of the webcast will be available via>ir.roche.com  *privacy notice  Best regards,   Bruno EschliHead of Investor Relations  Sabine Borngr äberInvestor Relations Officer  Roche Investor Relations Dr. Karl MahlerPhone: [phone]e-mail:[e-mail] Dr. Sabine Borngr äberPhone: [phone]e-mail:sabine....

Source: Roche Investor Update - February 7, 2022 Category: Pharmaceuticals Source Type: news